全文获取类型
收费全文 | 15440篇 |
免费 | 970篇 |
国内免费 | 90篇 |
专业分类
耳鼻咽喉 | 159篇 |
儿科学 | 287篇 |
妇产科学 | 262篇 |
基础医学 | 2066篇 |
口腔科学 | 155篇 |
临床医学 | 1355篇 |
内科学 | 3683篇 |
皮肤病学 | 273篇 |
神经病学 | 1704篇 |
特种医学 | 710篇 |
外科学 | 2704篇 |
综合类 | 34篇 |
一般理论 | 2篇 |
预防医学 | 686篇 |
眼科学 | 138篇 |
药学 | 1037篇 |
中国医学 | 19篇 |
肿瘤学 | 1226篇 |
出版年
2024年 | 12篇 |
2023年 | 108篇 |
2022年 | 174篇 |
2021年 | 474篇 |
2020年 | 227篇 |
2019年 | 456篇 |
2018年 | 539篇 |
2017年 | 361篇 |
2016年 | 361篇 |
2015年 | 444篇 |
2014年 | 691篇 |
2013年 | 805篇 |
2012年 | 1284篇 |
2011年 | 1325篇 |
2010年 | 740篇 |
2009年 | 711篇 |
2008年 | 1072篇 |
2007年 | 1011篇 |
2006年 | 1036篇 |
2005年 | 913篇 |
2004年 | 870篇 |
2003年 | 716篇 |
2002年 | 697篇 |
2001年 | 139篇 |
2000年 | 109篇 |
1999年 | 130篇 |
1998年 | 131篇 |
1997年 | 115篇 |
1996年 | 88篇 |
1995年 | 79篇 |
1994年 | 70篇 |
1993年 | 47篇 |
1992年 | 63篇 |
1991年 | 42篇 |
1990年 | 35篇 |
1989年 | 51篇 |
1988年 | 50篇 |
1987年 | 34篇 |
1986年 | 34篇 |
1985年 | 32篇 |
1984年 | 23篇 |
1983年 | 21篇 |
1982年 | 14篇 |
1975年 | 14篇 |
1974年 | 14篇 |
1972年 | 16篇 |
1971年 | 15篇 |
1970年 | 18篇 |
1969年 | 14篇 |
1968年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
Olivier Duron Rachid Koual Lise Musset Marie Buysse Yann Lambert Benoît Jaulhac Denis Blanchet Kinan Drak Alsibai Yassamine Lazrek Loïc Epelboin Pierre Deshuillers Cline Michaud Maylis Douine 《Emerging infectious diseases》2022,28(8):1673
We report a case of unusual human anaplasmosis in the Amazon rainforest of French Guiana. Molecular typing demonstrated that the pathogen is a novel Anaplasma species, distinct to all known species, and more genetically related to recently described Anaplasma spp. causing infections in rainforest wild fauna of Brazil. 相似文献
73.
Laura Garcia Tom Woudenberg Jason Rosado Adam H. Dyer Franoise Donnadieu Delphine Planas Timothe Bruel Olivier Schwartz Thierry Prazuck Aurlie Velay Samira Fafi-Kremer Isabella Batten Conor Reddy Emma Connolly Matt McElheron Sean P. Kennelly Nollaig M. Bourke Michael T. White Stphane Pelleau 《Viruses》2022,14(7)
Serological assays capable of measuring antibody responses induced by previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been critical tools in the response to the COVID-19 pandemic. In this study, we use bead-based multiplex assays to measure IgG and IgA antibodies and IgG avidity to five SARS-CoV-2 antigens (Spike (S), receptor-binding domain (RBD), Nucleocapsid (N), S subunit 2, and Membrane-Envelope fusion (ME)). These assays were performed in several cohorts of healthcare workers and nursing home residents, who were followed for up to eleven months after SARS-CoV-2 infection or up to six months after vaccination. Our results show distinct kinetic patterns of antibody quantity (IgG and IgA) and avidity. While IgG and IgA antibody levels waned over time, with IgA antibody levels waning more rapidly, avidity increased with time after infection or vaccination. These contrasting kinetic patterns allow for the estimation of time since previous SARS-CoV-2 infection. Including avidity measurements in addition to antibody levels in a classification algorithm for estimating time since infection led to a substantial improvement in accuracy, from 62% to 78%. The inclusion of antibody avidity in panels of serological assays can yield valuable information for improving serosurveillance during SARS-CoV-2 epidemics. 相似文献
74.
Franz Buchegger Valentina Garibotto Thomas Zilli Laurent Allainmat Sandra Jorcano Hansjörg Vees Olivier Rager Charles Steiner Habib Zaidi Yann Seimbille Osman Ratib Raymond Miralbell 《European journal of nuclear medicine and molecular imaging》2014,41(1):68-78
Purpose
18F-Fluorocholine (FCH) and 11C-acetate (ACE) PET are widely used for detection of recurrent prostate cancer (PC). We present the first results of a comparative, prospective PET/CT study of both tracers evaluated in the same patients presenting with recurrence and low PSA to compare the diagnostic information provided by the two tracers.Methods
The study group comprised 23 patients studied for a rising PSA level after radical prostatectomy (RP, 7 patients, PSA ≤3 ng/ml), curative radiotherapy (RT, 7 patients, PSA ≤5 ng/ml) or RP and salvage RT (9 patients, PSA ≤5 ng/ml). Both FCH and ACE PET/CT scans were performed in a random sequence a median of 4 days (range 0 to 11 days) apart. FCH PET/CT was started at injection (307?±?16 MBq) with a 10-min dynamic acquisition of the prostate bed, followed by a whole-body PET scan and late (45 min) imaging of the pelvis. ACE PET/CT was performed as a double whole-body PET scan starting 5 and 22 min after injection (994?±?72 MBq), and a late view (45 min) of the prostate bed. PET/CT scans were blindly reviewed by two independent pairs of two experienced nuclear medicine physicians, discordant subgroup results being discussed to reach a consensus for positive, negative end equivocal results.Results
PET results were concordant in 88 out of 92 local, regional and distant findings (Cohen’s kappa 0.929). In particular, results were concordant in all patients concerning local status, bone metastases and distant findings. Lymph-node results were concordant in 19 patients and different in 4 patients. On a per-patient basis results were concordant in 22 of 23 patients (14 positive, 5 negative and 3 equivocal). In only one patient was ACE PET/CT positive for nodal metastases while FCH PET/CT was overall negative; interestingly, the ACE-positive and FCH-negative lymph nodes became positive in a second FCH PET/CT scan performed a few months later.Conclusion
Overall, ACE and FCH PET/CT showed excellent concordance, on both a per-lesion and a per-patient basis, suggesting that both tracers perform equally for recurrent prostate cancer staging. 相似文献75.
76.
77.
Olivier Moranne Cécile Couchoud Anne Kolko-Labadens Vincent Allot Coraline Fafin Cécile Vigneau 《Néphrologie & thérapeutique》2012,8(7):516-520
In France, the incidence of dialysis patients is increasing in people over 75 years and represents 40% of incident patients. In these elderly patients with many comorbidities, the benefit of dialysis in terms of survival and quality of life remains controversial. Using data from REIN, determinants of early mortality were identified and a prognostic score was provided. This approach must now be adapted to elderly with end stage renal failure (ESRF) not on dialysis for which we have little data on their clinical characteristics, therapeutic projects and outcome. We report the results of a pilot study and the prospective study protocol that resulted. In four French nephrology department, 76 patients were studied with a mean age of 83 ± 5 years, with a MDRD estimated GFR (abbreviated MDRD) of 16 ± 4 mL/min/1.73 m2. These patients were different from the population on dialysis recorded in REIN. This pilot study has shown the feasibility of a prospective study on a larger scale, which aims to build a valuable tool for decision making in elderly patients with ESRF not yet on dialysis. 相似文献
78.
Pierre Delanaye Christophe Mariat Olivier Moranne Etienne Cavalier Martin Flamant 《Néphrologie & thérapeutique》2012,8(4):199-205
Measuring or estimating glomerular filtration rate (GFR) is still considered as the best way to apprehend global renal function. In 2009, the new Chronic Kidney Disease Epidemiology (CKD-EPI) equation has been proposed as a better estimator of GFR than the Modification of Diet in Renal Disease (MDRD) study equation. This new equation is supposed to underestimate GFR to a lesser degree in higher GFR levels. In this review, we will present and deeply discuss the performances of this equation. Based on articles published between 2009 and 2012, this review will underline advantages, notably the better knowledge of chronic kidney disease prevalence, but also limitations of this new equation, especially in some specific populations. We eventually insist on the fact that all these equations are estimations and nephrologists should remain cautious in their interpretation. 相似文献
79.
Leenhardt A Defaye P Mouton E Delay M Delarche N Dupuis JM Bizeau O Mabo P Cheggour S Babuty D;on behalf of the OPERA Registry investigators 《Europace : European pacing, arrhythmias, and cardiac electrophysiology》2012,14(10):1465-1474
AIMS: Inappropriate therapy delivered by implantable cardioverter defibrillators (ICDs) remains a challenge. The OPERA registry measured the times to, and studied the determinants of, first appropriate (FAT) and inappropriate (FIT) therapies delivered by single-, dual- and triple-chamber [cardiac resynchronization therapy defibrillator (CRT-D)] ICD. METHODS AND RESULTS: We entered 636 patients (mean age = 62.0 ± 13.5 years; 88% men) in the registry, of whom 251 received single-, 238 dual-, and 147 triple-chamber ICD, for primary (30.5%) or secondary (69.5%) indications. We measured times to FAT and FIT as a function of multiple clinical characteristics, examined the effects of various algorithm components on the likelihood of FAT and FIT delivery, and searched for predictors of FAT and FIT. Over 22.8 ± 8.8 months of observation, 184 patients (28.9%) received FAT and 70 (11.0%) received FIT. Ventricular tachycardia (VT) was the trigger of 88% of FAT, and supraventricular tachycardia was the trigger of 91% of FIT. The median times to FIT (90 days; range 49-258) and FAT (171 days; 50-363) were similar. The rate of FAT was higher (P <0.001) in patients treated for secondary than primary indications, while that of FIT were similar in both groups. Out of 57 analysable FIT, 27 (47.4%) could have been prevented by fine tuning the device programming like the sustained rate duration or the VT discrimination algorithm. CONCLUSIONS: First inappropriate therapy occurred in 11% of 636 ICD recipients followed for ~2 years. Nearly 50% of FIT could have been prevented by improving device programming. 相似文献
80.
Olivier Devuyst 《Peritoneal dialysis international》2013,33(5):472-Oct;33(5):472